Intermittent |
Symptoms < once a week |
Brief exacerbations |
Nocturnal symptoms not > twice a month |
• FEV1 or PEF ≥ 80% predicted |
• PEF or FEV1 variability < 20% |
Mild persistent |
Symptoms > once a week but < once a day |
Exacerbations may affect activity and sleep |
Nocturnal symptoms > twice a month |
• FEV1 or PEF ≥ 80% predicted |
• PEF or FEV1 variability < 20-30% |
Moderate persistent |
Symptoms daily |
Exacerbations may affect activity and sleep |
Nocturnal symptoms > once a week |
Daily use inhaled short-acting β2-agonist |
• FEV1 or PEF 60-80% predicted |
• PEF or FEV1 variability > 30% |
Severe persistent |
Symptoms daily |
Frequent exacerbations |
Frequent nocturnal asthma symptoms |
Limitation of physical activities |
• FEV1 or PEF ≤ 60% predicted |
• PEF or FEV1 variability > 30% |